A comeback for checkpoint inhibition in multiple myeloma

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-08-26 DOI:10.1038/s43018-024-00803-3

Maximilian Merz

引用次数: 0

Abstract

Early trials of immune checkpoint inhibitors (ICIs) in multiple myeloma (MM) showed increased mortality, halting their development. A study now reports promising results and distinct changes in the immune microenvironment after TIGIT and LAG3 blockade in heavily pre-treated patients with MM, marking a potential revival for ICIs in MM therapy.

Abstract Image

查看原文本刊更多论文

检查点抑制剂在多发性骨髓瘤中卷土重来。

免疫检查点抑制剂（ICIs）在多发性骨髓瘤（MM）中的早期试验显示死亡率增加，从而停止了其开发。现在，一项研究报告了在重度预处理 MM 患者中阻断 TIGIT 和 LAG3 后取得的可喜成果和免疫微环境的明显变化，这标志着 ICIs 在 MM 治疗中的潜在复兴。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.